Safety and efficacy of stereotactic body radiation therapy combined with S-1 simultaneously followed by sequential S-1 as an initial treatment for locally advanced pancreatic cancer (SILAPANC) trial: study design and rationale of a phase II clinical trial

Xiaofei Zhu, Xiaoping Ju, Fei Cao, Fang Fang, Shuiwang Qing, Yuxin Shen, Zhen Jia, Yangsen Cao, Huojun Zhang, Xiaofei Zhu, Xiaoping Ju, Fei Cao, Fang Fang, Shuiwang Qing, Yuxin Shen, Zhen Jia, Yangsen Cao, Huojun Zhang

Abstract

Introduction: Upfront surgeries are not beneficial to most patients with pancreatic cancer. Therefore, more emphasis has been placed chemoradiotherapy in locally advanced pancreatic cancer recently. Gemcitabine-based regimens or FOLFIRINOX (a chemotherapy regimen including leucovorin, 5-FU, irinotecan, oxaliplatin) has been proven as a standard chemotherapy in pancreatic cancer. However, severe toxicities may prevent the completion of chemotherapy. S-1 has showed better objective response rates, similar overall survival rates and progression-free survival rates compared with gemcitabine, revealing that S-1 may be a potential candidate in treating pancreatic cancer, especially for patients refractory to gemcitabine. Additionally, stereotactic body radiation therapy with Cyberknife could provide better efficacy than conventional radiotherapy in pancreatic cancer. Therefore, Cyberknife with S-1 simultaneously followed by sequential S-1 as an initial treatment may bring about favourable outcomes but needs further studies.

Methods and analysis: The S-1 as an initial treatment for locally advanced pancreatic cancer (SILAPANC) trial is a prospective, single-centre, one armed ongoing study. 190 eligible patients are required to initially receive Cyberknife with 1 cycle of S-1 simultaneously. After the concurrent chemoradiotherapy, 2 or 3 cycles of S-1 are sequentially given. Doses and fractions depend on the locations and volumes of tumours and the adjacent organs at risk. S-1 is taken orally, 2 times a day, at a dose of 80 mg/m2 for 28 days, followed by a 14-day interval. The primary objectives are overall survival and 1-year, 2-year, 3-year, 4-year and 5-year overall survival rates. The secondary objectives are cancer-specific survival, progression-free survival, time to progression, local control rates, clinical benefit rates, radiation-induced acute and late toxicities, adverse effects of chemotherapy and quality of life of patients. Besides, variables most predictive of prognosis would be identified via multivariate methods.

Ethics and dissemination: Approvals have been granted by the Changhai Hospital Ethics Committee (CHEC-2016-032-01). The results will be disseminated in peer-reviewed journals and at conferences.

Trial registration number: NCT02704143; Pre-results.

Conflict of interest statement

Conflicts of Interest: None declared.

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.

Figures

Figure 1
Figure 1
Illustrates the flow diagram of the study. SBRT, stereotactic body radiation therapy.

References

    1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10–29. 10.3322/caac.20138
    1. Sener SF, Fremgen A, Menck HR et al. . Pancreatic cancer: a report of treatment and survival trends for 100313 patients diagnosed from 1985–1995 using the national cancer database. J Am Coll Surg 1999;189:1–7. 10.1016/S1072-7515(99)00075-7
    1. Richter A, Niedergethmann M, Sturm JW et al. . Long-term results of partial pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head: 25-year experience. World J Surg 2003;27:324–9. 10.1007/s00268-002-6659-z
    1. Tseng JF, Raut CP, Lee JE et al. . Pancreaticoduodenectomy with vascular resection: margin status and survival duration. J Gastrointest Surg 2004;8:935–49. 10.1016/j.gassur.2004.09.046
    1. Hoyer M, Roed H, Sengelov L et al. . Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma. Radiother Oncol 2005;76:48–53. 10.1016/j.radonc.2004.12.022
    1. Burris HA III, Moore MJ, Andersen J et al. . Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403–13. 10.1200/jco.1997.15.6.2403
    1. Ueno H, Okusaka T, Ikeda M et al. . An early phase II study of S-1 in patients with metastatic pancreatic cancer. Oncology 2005;68:171–8. 10.1159/000086771
    1. Ueno H, Ioka T, Ikeda M et al. . Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. J Clin Oncol 2013;31:1640–8. 10.1200/JCO.2012.43.3680
    1. Morizane C, Okusaka T, Furuse J et al. . A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer. Cancer Chemother Pharmacol 2009;63:313–19. 10.1007/s00280-008-0741-7
    1. Sudo K, Yamaguchi T, Nakamura K et al. . Phase II study of S-1 in patients with gemcitabine-resistant advanced pancreatic cancer. Cancer Chemother Pharmacol 2011;67:249–54. 10.1007/s00280-010-1311-3
    1. Mizuno N, Yamao K, Komatsu Y et al. . Randomized phase II trial of S-1 versus S-1 plus irinotecan (IRIS) in patients with gemcitabine refractory pancreatic cancer. J Clin Oncol 2012;30:abstr 263.
    1. Ohkawa S, Okusaka T, Isayama H et al. . Randomised phase II trial of S-1 plus oxaliplatin vs S-1 in patients with gemcitabine-refractory pancreatic cancer Br J Cancer 2015;112:1428–34.
    1. Ge F, Xu N, Bai Y et al. . S-1 as monotherapy or in combination with leucovorin as second-line treatment in gemcitabine-refractory advanced pancreatic cancer: a randomized, open-label, multicenter, phase II study. Oncologist 2014;19:1133–4. 10.1634/theoncologist.2014-0223
    1. Rich TA, Shepard RC, Mosley ST. Four decades of continuing innovation with fluorouracil: current and future approaches to fluorouracil chemoradiation therapy. J Clin Oncol 2004;22:2214–32. 10.1200/JCO.2004.08.009
    1. Moningi S, Marciscano AE, Rosati LM et al. . Stereotactic body radiation therapy in pancreatic cancer: the new frontier. Expert Rev Anticancer Ther 2014;14:1461–75. 10.1586/14737140.2014.952286
    1. Berber B, Sanabria JR, Braun K et al. . Emerging role of stereotactic body radiotherapy in the treatment of pancreatic cancer. Expert Rev Anticancer Ther 2013;13:481–7. 10.1586/era.13.19
    1. Chuong MD, Springett GM, Freilich JM et al. . Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated. Int J Radiat Oncol Biol Phys 2013;86:516–22. 10.1016/j.ijrobp.2013.02.022
    1. Herman JM, Chang DT, Goodman KA et al. . Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma. Cancer 2015;121:1128–37. 10.1002/cncr.29161
    1. Mahadevan A, Jain S, Goldstein M et al. . Stereotactic body radiotherapy and gemcitabine for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2010;78:735–42. 10.1016/j.ijrobp.2009.08.046
    1. Koong AC, Le QT, Ho A et al. . Phase I study of stereotactic radiosurgery in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2004;58:1017–21. 10.1016/j.ijrobp.2003.11.004
    1. Koong AC, Christofferson E, Le QT et al. . Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2005;63:320–3. 10.1016/j.ijrobp.2005.07.002
    1. Schellenberg D, Goodman KA, Lee F et al. . Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2008;72:678–86. 10.1016/j.ijrobp.2008.01.051
    1. Schellenberg D, Kim J, Christman-Skieller C et al. . Single-fraction stereotactic body radiation therapy and sequential gemcitabine for the treatment of locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2011;81:181–8. 10.1016/j.ijrobp.2010.05.006
    1. Mahadevan A, Miksad R, Goldstein M et al. . Induction gemcitabine and stereotactic body radiotherapy for locally advanced nonmetastatic pancreas cancer. Int J Radiat Oncol Biol Phys 2011;81:e615–22. 10.1016/j.ijrobp.2011.04.045
    1. Polistina F, Costantin G, Casamassima F et al. . Unresectable locally advanced pancreatic cancer: a multimodal treatment using neoadjuvant chemoradiotherapy (gemcitabine plus stereotactic radiosurgery) and subsequent surgical exploration. Ann Surg Oncol 2010;17:2092–101. 10.1245/s10434-010-1019-y
    1. Rwigema JC, Parikh SD, Heron DE et al. . Stereotactic body radiotherapy in the treatment of advanced adenocarcinoma of the pancreas. Am J Clin Oncol 2011;34:63–9. 10.1097/COC.0b013e3181d270b4
    1. Gurka MK, Collins SP, Slack R et al. . Stereotactic body radiation therapy with concurrent full-dose gemcitabine for locally advanced pancreatic cancer: a pilot trial demonstrating safety. Radiat Oncol 2013;8:44 10.1186/1748-717X-8-44
    1. Didolkar MS, Coleman CW, Brenner MJ et al. . Image-guided stereotactic radiosurgery for locally advanced pancreatic adenocarcinoma results of first 85 patients. J Gastrointest Surg 2010;14:1547–59. 10.1007/s11605-010-1323-7
    1. Goyal K, Einstein D, Ibarra RA et al. . Stereotactic body radiation therapy for nonresectable tumors of the pancreas. J Surg Res 2012;174:319–25. 10.1016/j.jss.2011.07.044
    1. NCCN guidelines ‘Pancreatic adenocarcinoma’, version 2.2015.
    1. Benedict SH, Yenice KM, Followill D et al. . Stereotactic body radiation therapy: the report of AAPM Task Group 101. Med Phys 2010;37:4078–101. 10.1007/s10434-001-0123-4
    1. Breslin TM, Hess KR, Harbison DB et al. . Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration. Ann Surg Oncol 2001;8:123–32. 10.1007/s10434-001-0123-4
    1. Laurence JM, Tran PD, Morarji K et al. . A systematic review and meta-analysis of survival and surgical outcomes following neoadjuvant chemoradiotherapy for pancreatic cancer. J Gastrointest Surg 2011;15:2059–69. 10.1007/s11605-011-1659-7

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir